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Background: This study explores different approaches to estimate the clearance rate
of the reference tissue (k′2) parameter used for pharmacokinetic modeling, using the
simplified reference tissue model 2 (SRMT2) and further explores the effect on the binding
potential (BPND) of
11C-labeled Pittsburgh Compound B (PIB) PET scans.
Methods: Thirty subjects underwent a dynamic PIB PET scan and were classified as
PIB positive (+) or negative (–). Thirteen regions were defined from where to estimate k′2:
the whole brain, eight anatomical region based on the Hammer’s atlas, one region based
on a SPM comparison between groups on a voxel level, and three regions using different
BPSRTMND thresholds.
Results: The different approaches resulted in distinct k′2 estimations per subject.
The median value of the estimated k′2 across all subjects in the whole brain was
0.057. In general, PIB+ subjects presented smaller k′2 estimates than this median, and
PIB–, larger. Furthermore, only threshold and white matter methods resulted in non-
significant differences between groups. Moreover, threshold approaches yielded the best
correlation betweenBPSRTMND andBP
SRTM2
ND for both groups (R
2 = 0.85 for PIB+, and R2 =
0.88 for PIB–). Lastly, a sensitivity analysis showed that overestimating k′2 values resulted
in less biased BPSRTM2ND estimates.
Conclusion: Setting a threshold on BPSRTMND might be the best method to estimate k
′
2
in voxel-based modeling approaches, while the use of a white matter region might be a
better option for a volume of interest based analysis.
Keywords: Alzheimer’s disease, pharmacokinetic modeling, Pittsburgh compound B, SRTM, SRTM2
INTRODUCTION
Current research suggests that Alzheimer’s disease (AD) is associated with an abnormal deposition
of the amyloid-β (Aβ) peptide in the brain [1, 2]. These Aβ deposits may lead to progressive
dysfunction and nerve cells death, resulting in a neurodegenerative process [3]. It is possible to
assess this deposition in-vivo through the use of the 11C-labeled Pittsburgh Compound B (PIB)
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radiotracer in positron emission tomography (PET) studies
[4–6]. A simple visual assessment of standardized uptake value
(SUV) images, derived from these PET scans, might suffice to
assess whether or not there is Aβ deposition. However, through
pharmacokinetic modeling of dynamic PIB PET scans, it might
be possible to further classify the amount of deposition in the
brain [7].
Previous studies have already confirmed that the simplified
reference tissue model (SRTM) [8] is the preferred method for
pharmacokinetic modeling of PIB when arterial input is not
available [9, 10]. However, improvements on the accuracy of the
model can be done by coupling parameters [11] thereby reducing
the number of variables to be fitted by the model. The simplified
reference tissue model 2 (SRTM2) [12] has been validated as a
model “with better accuracy and precision” [10] than the original
SRTM, and has been frequently used in AD PET studies [13–16].
SRTM is a model that fits three parameters: binding potential
(BPND), relative tracer flow (R1), and clearance rate constant
of the reference region (k′2). Meanwhile, SRTM2 is a model
fitted in two runs. During the first run, SRTM is used to obtain
an estimate for k2
′ for each voxel in the image. This value is
then fixed to the median k′2 using voxels outside the reference
region. Next, a second run is done, fitting the two remaining
parameters (BPND and R1), thus reducing the noise in the specific
binding estimates and functional images. SRTM and SRTM2were
originally developed for the analysis of neuroreceptor binding.
Furthermore, SRTM2 was implemented with the intention of
reducing noise levels of the model parameters using a well-
defined receptor-rich region for the k′2 estimation. Nonetheless,
this assumption might be violated in the case of PIB, especially in
healthy subjects, who are not expected to have Aβ deposition.
Previous studies using SRTM2 for pharmacokinetic modeling
employed different approaches for k′2 estimation. For example,
this parameter was evaluated by coupling all target time activity
curves for radiotracers designed for D2/D3 receptors [17, 18] and
radioligands with a high affinity for the serotonin transporter
[19]. Tracers such as [11C]P943 [20], used for quantifying
serotonin 5-HT1B receptors, use the median value of the k′2
estimation for all voxels that have a BPSRTMND value between 0.5
and 4, and [18F]DPA-714 [21], used for neuroinflammation, the
median of all k′2 values from all voxels in the image.
However, Aβ deposits are not evenly distributed across the
brain [22], and change over time with AD progression [3].
Therefore, there are no well-defined receptor-rich regions. Other
radiotracers, such as [18F]Florbetaben [23], [18F]Flutemetamol
[24], and [18F]Florbetapir [25], which also bind to the Aβ
plaques, present the same issue. Studies with these tracers
have either used SRTM or SRTM2, estimating k′2 from all
voxels of the image outside the reference region. This approach
can be challenging in studies that include subjects without
amyloid deposition, because the signal is not as high as in
subjects that present these deposits. This lack of signal might
result in noisy images, which may reduce the reliability of the
estimations of the parameters from themodels. In the case of PIB,
previous investigations performed a pharmacokinetic analysis
using SRTM [26, 27], reference Logan [28], and SRTM2 [10, 13–
16]. Yet, there is no consensus on how the k′2 estimation should be
done. Some studies take the mean SRTM-derived k′2 value from
all target regions [13, 14], while others set a minimum threshold
on the BPSRTMND parametric map to select the voxels being used
for the k′2 estimation [10, 15, 16]. To the best of the authors’
knowledge, the effects that these approaches to estimate k′2 have
in the final BPND value, have not yet been explored.
Therefore, the aim of this study was to examine the
consequences of estimating k′2 using different approaches, and to
define an optimal method for estimating k′2 for the analysis of
dynamic PIB PET studies using SRTM2.
MATERIALS AND METHODS
Subjects
A cohort of 30 subjects, which were available at the moment
of performing this study, was selected from a larger ongoing
study at the memory clinic of the University Medical Center
of Groningen (UMCG), Groningen, The Netherlands. Written
informed consent to participate in the study was provided.
The study was conducted in agreement with the Declaration of
Helsinki and subsequent revisions and approved by the Medical
Ethical Committee of the UMCG (2014/320).
Patients were clinically diagnosed, by consensus in a
multidisciplinary team, either with Alzheimer’s Disease (AD),
according to the National Institute on Aging and Alzheimer’s
Association criteria (NIA-AA) [29], or with mild cognitive
impairment (MCI), in agreement with the Petersen criteria [30].
Healthy controls (HC) had no cognitive complaints and a mini-
mental state examination score above 28. All subjects underwent
standard dementia screening, and multimodal neuroimaging,
including PIB PET scans and T1-3D magnetic resonance
imaging (MRI). After the PIB PET scan, clinical diagnoses
were reconsidered, according to the National Institute on Aging
and the Alzheimer’s Association Research supposed Framework
[1]. Subjects were then divided into two categories, based on
visual inspections of cortical levels of PIB binding, as “PIB+,”
if binding levels were high, and “PIB–,” if they were low.
The demographic characteristics of subjects are presented in
Supplementary Table 1.
PET Acquisition
Subjects underwent a dynamic PIB PET scan under standard
resting conditions with closed eyes. Scans were performed with
either a Siemens Biograph 40 or 64 mCT PET scan (Siemens
Medical Solutions, USA). Both systems were from the same
vendor and from the same generation; the acquisition and
reconstruction protocols were harmonized, and the systems
were (cross-) calibrated. Therefore, no significant differences
were expected from the images provided by these two different
scanners. Nonetheless, a comparison between the data used in
this study, provided from the different scanners, was made using
a t-test and, as expected, no significant results were found.
PIB tracer was synthesized at the radiopharmacy facility at the
Nuclear Medicine and Molecular Imaging department at the
UMCG, according to Good Manufacturing Practice. The tracer
was administered via a venous cannula, and the acquisition
started simultaneously with the PIB injection (379 ± 46 MBq).
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FIGURE 1 | Resemblance of the generated VOIs to be used on the estimation of k′2 organized by approaches: a VOI for the whole masked image, eight volumes
based on anatomical structures (Cerebrum + Brainstem, White Matter + Brainstem, Brainstem, White Matter, Gray Matter, Frontal Lobe, Parietal Lobe, and Temporal
Lobe), three volumes based on different BPSRTMND thresholds (Threshold 0.01, Threshold 0.05, Threshold 0.1), and one volume based on the statistical differences
between groups on a voxel level.
Dynamic PIB PET acquisition lasted for at least 60min (frames:
7× 10 s, 3× 30 s, 2× 60 s, 2× 120 s, 2× 180 s, 5× 300 s, and 2×
600 s). List-mode data from PET scans were reconstructed using
3DOSEM (three iterations and 24 subsets), point spread function
correction and time-of-flight, resulting in images with 400 ×
400 × 111 matrix, isotropic 2mm voxels, smoothed with a 2
mm-Gaussian filter at Full Width and Half Maximum (FWHM).
Image Processing
Registration and data collection from the images were done using
the PMOD software package (version 3.8; PMOD Technologies
LLC). Using tissue probability maps [31], the T1 3D MRI scans
were spatially normalized to the Montreal Neurologic Institute
space. To define the anatomical brain regions, the Hammers
atlas [32] was selected. A total of 77 regions were drawn, with
right and left side separated and white matter distinguished
from cortical tissue. Some regions from the original atlas were
excluded: cerebellar white matter, the corpus callosum, the third
ventricle, the lateral ventricles, and the temporal horns. The PET
images were corrected for motion using the average of the first 12
frames and were then aligned to the MRI in individual space. The
PET images were also smoothed with a Gaussian filter of 6mm at
FWHM, and voxels that were outside of the brain were masked.
Pharmacokinetic Modeling
Parametric images were generated using pharmacokinetic
modeling of the dynamic PIB PET at a voxel level in individual
space, and it was done in three steps: (1) a first estimate of
the BPSRTMND , R1, and efflux constant of the reference region (k
′
2)
was obtained using a basis function implementation of SRTM
[8]; (2) the k′2 parameter was then fixed to the median k
′
2
value of all voxels in a predefined volume of interest (VOI);
and (3) the final parametric BPSRTM2ND map was estimated using
SRTM2 [12]. Thirteen approaches were used to generate VOIs to
estimate the median k′2 (Supplementary Table 2, Figure 1): one
approach containing all voxels of the masked brain image, eight
approaches based on predefined anatomical structures or VOIs,
three approaches based on selecting voxels using fixed BPSRTMND
thresholds, and one VOI approach defined by voxels having a
statistically significant difference between the images of each
group (SPM). These statistical comparisons at voxel level were
performed in SPM12 (Wellcome Trust Center for Neuroimaging,
UK) with a two-sample t-test, and T-maps interrogated at p =
0.005 (uncorrected) and only clusters with p< 0.05, corrected for
family-wise error, were considered significant. Then these VOIs
were projected onto the k′2 parametricmaps and themedian value
[12] of the voxels within the volumes were taken and used for
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the generation of the final parametric BPND maps with SRTM2
(BPSRTM2ND ). The gray matter of the cerebellum was used as a
reference region due to its lack, or very late presentation, of
specific PIB binding [4, 33–35]. The imposed restriction on the
range of possible apparent uptake rate constant (k2a) values, with
a minimum of 0.01 and a maximum of 0.3, and 80 basis functions
was used. These settings were applied to both the basis function
implementations of SRTM and SRTM2. The R1 parameter was
not considered in this study as it is insensitive to small changes in
the fixed k′2 [8, 14].
Histograms of k′2 distribution were constructed using voxel
values within the VOIs of the average parametric maps per group.
Statistical Analyses
A two sample t-test was performed to evaluate differences in k′2
estimations between the groups. Moreover, since the standard
approach from SRTM2 to estimate k′2 is to consider all voxels of
the masked brain image outside of the cerebellum, a paired t-test
was done to assess the discrepancy between the values yielded
by the Whole Brain and the other methods. This approach has
been used before in studies with other radiotracers that do not
have a region with specific binding [36]. Boxplots of the k′2
distributions for each method were also generated. Comparisons
between PIB+ and PIB– groups for eachmethod were done using
a t-test.
To explore the effect of the applied k′2 value on BP
SRTM2
ND , a
sensitivity analysis was done, where the k′2 parameter was fixed
to a range of values from 0.005 to 0.09 (with steps of 0.005),
and the BPSRTM2ND parametric maps were generated for each k
′
2.
BPSRTM2ND values were retrieved from these images for all brain
regions. This effect was plotted with the fixed k′2 values minus
the median k′2 of all subjects for theWhole Brain method, against
the difference between BPSRTM2ND of the fixed k
′
2 value and the
average BPSRTM2ND of all subjects in the Whole Brain method. In
this study, it was chosen to report the BPND values, nevertheless
the results also apply to the distribution volume ratio (DVR) as
the values distinguish only by an offset of 1 [11]. Three brain
regions were chosen to be shown: a region with high binding
(Superior Parietal Gyrus left), a region with medium binding
(Inferior Frontal Gyrus right), and a region with low PIB binding
(Lateral Remainder of Occipital Lobe right).
A scatter plot was made to visually assess the correlation
between the BPSRTM2ND and BP
SRTM
ND estimations. Then a general
linear model was used to compare the values, with the BPSRTM2ND
estimations as the independent variable and the BPSRTMND as the
dependent variable.
A Bland-Altman plot was made to evaluate the agreement
between the two BPND measurements. A p-value of 0.05 was
used as a significance threshold for all statistical analyses, and
no correction for multiple comparisons was made. All statistical
FIGURE 2 | Median k′2 parametric maps of all subjects from the PIB+ (top left), and PIB– (left bottom) groups. Shown are corresponding transaxial, and sagittal slices
of the brain. Color scales were adjusted to the same range. On the right, the histograms containing the counts of k′2 values from the voxels of the parametric maps on
the left. Black dots and lines correspond to voxels contained inside the Whole Brain VOI, in red, of voxels from the Gray Matter VOI, and in blue, from the White Matter.
The range of the histograms was adjusted to the same range of the color scale of the parametric maps.
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FIGURE 3 | Distribution of individual subject’s k′2 values per group for all methods. The boxes show the interquartile range of distribution, the solid line shows the
median k′2 value for the group, the whiskers expand up to 1.5 times the interquartile range, and the further points are the outlier subjects. In white, the values from the
PIB– subjects, and in gray, from the PIB+ patients. The dashed line corresponds to the median value from all subjects combined for the Whole Brain method.
The stars show which methods presented a significant difference between groups resulting from the t-tests.
analyses were made using RStudio [RStudio version 1.1.423,
R version 3.4.3 [37]].
Criteria for Best Method Selection
To select the best method for estimating k′2, the 13 approaches
were ranked based on the following criteria, in order of
importance: (1) absence of significant differences in k′2 values
between the groups; (2) k′2 estimation closer to the median value
of the population; (3) high correlations between BPSRTMND and
BPSRTM2ND ; (4) linear regression’s result with a slope closest to 1,
and (5) an intercept closest to 0.
RESULTS
Parametric Maps
The k′2 parametric maps were noticeably different for PIB+
and PIB– subjects (Figure 2), with the main difference between
groups being an increase of gray matter voxel values in the
PIB– group. When observing the distribution of the k′2 values
of all voxels across the images, a discrepancy can be seen on
the height and position of the peaks and the variance of values
in the histograms (Figure 2). The PIB+ group had a peak at
0.04, and a median value of 0.05, while the PIB– group presented
values of 0.04 and 0.06, respectively. The histogram counts of gray
and white matter voxels of each image only, also revealed that
the main difference between groups was a wider distribution of
values in the gray matter voxels of PIB– subjects when compared
to PIB+ patients, although there was a shift in both peaks.
Efflux Parameter Estimation (k
′
2)
The VOI approaches for retrieving the median k′2 values yielded
different estimations (Figure 3). In general, gray matter VOIs
(i.e., GrayMatter, Frontal, Parietal, and Temporal Lobes) resulted
in a larger and statistically significant difference in k′2 estimations
between PIB+ and PIB– subjects, while white matter and
threshold VOIs did not (Supplementary Table 3). For the PIB+
group, the Parietal Lobe VOI presented the largest range of
k′2 distribution (range 0.03–0.09), and the Whole Brain, the
smallest one (0.04–0.08). For the PIB–, the largest range of
k′2 distribution was observed for the Frontal Lobe (0.04–0.13),
and the smallest for the Brainstem (0.06–0.09). Most methods
presented a statistically significant difference k′2 when compared
with the Whole Brain (Supplementary Table 4). Meanwhile,
the threshold approaches presented the smallest discrepancy in
k′2 for both groups, and, in general, this difference was not
statistically significant.
The median k′2 value using the Whole Brain method was
0.057, and the methods that presented the smallest range of
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FIGURE 4 | Plot of the relative changes in BPSRTM2ND with relative increment of k
′
2. In the x-axis is the fixed value of k
′
2 (which varied from 0.005 to 0.09 with a step of
0.005) minus the median k′2 from the data of all subjects for the Whole Brain method. In the y-axis is the BP
SRTM2
ND of the fixed k
′
2 value of a specific brain region minus
the value of the same region for the Whole Brain method. The dashed line represents a difference in BPSRTM2ND of zero. Black dots represent data from the Superior
Parietal Gyrus left region (a region with high PIB binding), in dark gray, the Inferior Frontal Gyrus right (a region with medium binding), and in light gray, the Lateral
Remainder of Occipital Lobe right (a region with low binding of PIB).
k′2 distribution, as well as having a mean k
′
2 closest to the
Whole Brain value, were Threshold 0.1 and, from the anatomical
approaches, the White Matter. The first method presented k′2
values of (mean± SD) 0.05± 0.01 (range 0.04–0.08) for the PIB+
group, and 0.06± 0.01 (0.05–0.07) for the PIB–. Additionally, the
latter resulted in values of 0.07 ± 0.01 (0.05–0.1) for the PIB+,
and 0.06 ± 0.01 (0.05–0.08) for the PIB–. This White Matter
method yielded, however, an overestimation of the k′2 parameter
of 31.8% for the PIB+ group, and 4.4% for the PIB–, when
compared to theWhole Brain. Supplementary Table 3 shows the
means, standard deviations, and ranges of k′2 per group for all
methods, along with the p-value of the t-test that compared the
k′2 differences between groups.
Sensitivity Analysis
When exploring the effect of k′2 estimations on the BP
SRTM2
ND , a
non-linear relationship between the parameters was observed.
This can be seen both in Figure 4, which shows the relative
change in BPSRTM2ND as a function of the fixed k
′
2 value relative
to the Whole Brain BPSRTM2ND , vs. the difference between the
fixed k′2 and the estimated value for the Whole Brain; and in
Supplementary Figure 1, which shows the BPSRTM2ND values for
each fixed k′2. Overall, all brain regions presented a similar
relationship: a steep increase of BPSRTM2ND with the increment of
k′2 values until it reaches a peak, followed by an exponential
decrease. It was also observed that the larger the fixed k′2, the
smaller the change in BPSRTM2ND was. It could further be seen that
for regions with more binding, the BPSRTM2ND was more sensitive
to deviations in k′2.
Correlation of Binding Potential Values
From SRTM and SRTM2
The general linear model suggested a strong correlation between
BPSRTMND and BP
SRTM2
ND for all methods (Table 1, Figure 5), with
higher R² values for PIB– subjects and with all results being
significant. For the PIB+ group, the smallest R² was 0.79, for
Frontal and Parietal Lobe methods, while the highest was 0.83
for Cerebrum + Brainstem, Temporal Lobe, Brainstem, and
threshold methods. For the PIB–, the smallest R² was 0.85 for the
Parietal Lobe, and the highest correlation was 0.88 for the Whole
Brain, Cerebrum + Brainstem, and the threshold methods. The
slope furthest from 1 was 0.67 for the PIB+ patients, when using
the White Matter + Brainstem method, while the closest to 1
slope was 0.95 when using the Parietal Lobe VOI. Additinally,
for the PIB– subjects, these values were, 0.99 when using the
SPM method, and 0.86 when using the Temporal Lobe VOI,
respectively. Thresholdmethods were not the closest to 1 for each
group individually, however this approach had the overall best
performance (slope of 0.86 for PIB+; and for PIB− 1.02, 1.03,
and 1.05 for Threshold 0.01, 0.05, and 0.1 respectively).
Bias Assessment
The bias between BPSRTMND and BP
SRTM2
ND for different methods
revealed a negative trend that was proportional to BPSRTMND for
the PIB+ patients, and showed a more disperse distribution for
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Whole brain R² 0.82 0.88
Intercept 0.05 −0.03
Slope 0.88 1.02
Cerebrum + brainstem R² 0.83 0.88
Intercept 0.05 −0.03
Slope 0.81 0.97
Gray matter R² 0.82 0.87
Intercept 0.06 −0.04
Slope 0.89 0.97
Frontal lobe R² 0.79 0.86
Intercept 0.10 −0.04
Slope 0.95 1.07
Parietal lobe R² 0.79 0.85
Intercept 0.10 −0.03
Slope 0.88 1.08
Temporal lobe R² 0.83 0.86
Intercept 0.03 −0.04
Slope 0.80 0.86
White matter R² 0.83 0.87
Intercept 0.04 −0.03
Slope 0.73 0.98
Brainstem R² 0.83 0.87
Intercept 0.04 −0.03
Slope 0.73 0.98
White matter + brainstem R² 0.81 0.87
Intercept 0.03 −0.04
Slope 0.67 0.88
Threshold 0.01 R² 0.83 0.88
Intercept 0.06 −0.03
Slope 0.86 1.02
Threshold 0.05 R² 0.83 0.88
Intercept 0.06 −0.02
Slope 0.86 1.03
Threshold 0.1 R² 0.83 0.88
Intercept 0.06 −0.02
Slope 0.86 1.05
SPM R² 0.81 0.87
Intercept 0.09 −0.04
Slope 0.86 0.99
All values were statistically significant.
the PIB– subjects (Figure 5, Table 2). Nearly all methods resulted
in a statistically significant bias in BPSRTM2ND for the PIB– group.
For the PIB+ group, the only methods that did not result in a
significant bias were the ones based on three different thresholds,
Gray Matter VOI, and SPM (Table 2). A wider range was
observed for the PIB+ patients (e.g., for theWhole Brain,−0.64–
0.86) than for the PIB– subjects (−0.32–0.29, same method).
The mean bias between BPSRTM2ND and BP
SRTM
ND when using the
Threshold 0.1 method was −0.04 ± 0.17 for the PIB+ group
(a bias of 2%, slope = 0.02, intercept = −0.05), and −0.01 ±
0.07 (a bias of 16%, slope= 0.16, intercept=−0.03) for the PIB–
group, and for the White Matter method, −0.15 ± 0.17 (a bias
of 15%, slope = −0.15, intercept = −0.05), and −0.03 ± 0.07 (a
bias of 8%, slope= 0.08, intercept=−0.04), respectively.
Ranking of the Methods
In summary, based on the results presented in the previous
section, the following ranking of the preferred methods to
estimate k′2 was: Threshold 0.1, Threshold 0.05, Threshold 0.01,
White Matter, White Matter + Brainstem, Brainstem, Whole
Brain, Cerebrum + Brainstem, Frontal Lobe, Gray Matter,
Parietal Lobe, SPM, Temporal Lobe.
DISCUSSION
In this study, different approaches of estimating the optimal k′2 to
be fixed in SRTM2 and their impact on BPSRTM2ND were explored.
The k′2 estimation is an important step in the pharmacokinetic
analysis of dynamic PIB PET scans using SRTM2, as a bias in
k′2 affects the obtained binding potential. Although SRTM2 has
already been validated as a suitablemodel for PIB studies [10], the
fact that there is no well-defined receptor-rich region might lead
to errors in the estimation of BPSRTM2ND , and an examination of the
consequences of wrongly determining k′2 has not yet been done.
For both PIB+ patients and PIB– subjects, the cerebellum is
a region without specific binding of Aβ tracers, so it can be used
as a reference region for the pharmacokinetic modeling of the
radiotracer using SRTM2 [4, 10, 33–35]. Thus it is not expected
that there will be a significant difference between groups when
estimating k′2, as has already been seen from previous studies
[38]. Therefore, it is important to consider this when selecting
a method.
The main difference between groups is that the PIB+ subjects
present an accumulation of Aβ plaques on the cortex [3], and
thus a higher binding of PIB in these areas, while the PIB–
subjects do not, as was seen in the histograms of Figure 2.
Because of this discrepancy, it was not a surprise that the SPM
VOI was composed mainly of gray matter voxels. Furthermore,
this distinction between k′2 group values is the most probable
explanation for the poor performance of gray matter (i.e.,
Gray Matter, Frontal, Parietal, and Temporal Lobes) and SPM
methods, especially in the PIB– group. This difference between
groups, which can be seen in Figure 2, also shows that not all
brain regions might be suitable for estimating k′2, as the value
for this parameter depends on which group the subject belongs
to. This further demonstrates that, although the theoretical
assumption of SRTM2 is that k′2 should be constant across the
brain, it is not the case in practice.
Moreover, threshold based approaches guarantee that only
voxels with some minimal elevated level of PIB binding were
included within the VOIs used for the k′2 estimation. Since PIB
does not have a specific target region, these methods might be the
best approaches when using SRTM2. Furthermore, this selection
of voxels may also explain why there was a smaller difference in
k′2 between groups for these methods (Figure 3).
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FIGURE 5 | Scatter plot showing BPSRTM2ND estimates (y-axis) from Threshold 0.1 (top left) and White Matter (top right), and BP
SRTM
ND values (x-axis). Lines resulting from
the linear regression applied to the data are also shown, a full line for the PIB+ group, and a dashed line for the PIB–. Results of the linear regression are given in boxes
at the bottom right corner of each plot. Bland-Altman plot showing the difference between the values of BPND assessed by different SRTM2 methods (by Threshold
0.1 on the bottom left, and by White Matter on the bottom right) from SRTM. The full line is at the mean difference values for the group, and the dashed lines delimit
the 95% agreement interval (at mean ± 1.96 × standard deviation). Dark gray circles represent data from the PIB– patients, and light gray, from the PIB+ subjects.
The preferred method for estimating k′2 should be using
plasma input. However, blood data is not always available, as
in the case of this study, and, therefore, there is a need for
finding the best way of estimating this parameter directly from
the image since it influences the BPSRTM2ND value. A previous study
by Price and colleagues [34] estimated these parameters using
plasma input compartmental modeling, and they found a ratio
of non-specific trapping ( k5
k6
) of 1.4 and an average clearance for
target tissues (k2) was of 0.144. With these measurements, an








a k′2 of 0.055. This value is close to the median k
′
2 value of 0.057
found in the present study. Interestingly, k′2 estimates using white
matter methods (i.e., White Matter, Brainstem, andWhite Matter
+ Brainstem) diverged the most from this expected value for
both groups. Meanwhile, gray matter methods only deviated for
the PIB– group. From this observation, it might be concluded
that regions without specific binding of PIB might result in a k′2
overestimation. Furthermore, PIB retention has been shown to
be similar in white matter for both AD patients and HC subjects
[4], which explains the absence of differences between groups for
these methods.
The results presented in the previous section showed that an
overestimation of k′2 might not be an issue as this would lead
to a smaller bias in BPSRTM2ND than when underestimating k
′
2.
Slight changes in low k′2 values yield larger shifts in BP
SRTM2
ND
estimation, while for larger k′2 values, smaller shifts in BP
SRTM2
ND
were observed. Because of this behavior, it is better to impose a
lower boundary on k′2, to secure a smaller bias in BP
SRTM2
ND . This
limit could be around 0.04, since most of the estimation across
methods and subjects were higher, and the sensitivity plot showed
larger biases for k′2 values below 0.04 (Supplementary Figure 1).
Because the actual k′2 estimation can be substantially different
between subjects, it is not recommended to fix k′2 to a single
value across all subjects or to use a population based value.
Based on all results presented, a ranking of the methods was
done. The method Threshold 0.1 was the one that presented
the highest correlation between BPSRTMND and BP
SRTM2
ND for both
groups. Moreover, it did not show a significant difference in
estimated k′2 between groups and resulted in a median k
′
2
Frontiers in Physics | www.frontiersin.org 8 December 2019 | Volume 7 | Article 212
Peretti et al. Optimization of k′2 in SRTM2 PIB PET Studies
TABLE 2 | Results from the bias assessment comparing BPSRTMND and BP
SRTM2
ND from different methods.
Method PIB Mean SD Min Max Intercept Slope p-value
Whole brain PIB+ −0.027 0.169 −0.645 0.856 −0.007 −0.030 0.022*
PIB– −0.024 0.066 −0.317 0.287 −0.035 0.085 <0.001*
Cerebrum + brainstem PIB+ −0.088 0.163 −0.677 0.747 −0.027 −0.094 <0.001*
PIB– −0.036 0.063 −0.323 0.223 −0.042 0.054 <0.001*
Gray matter PIB+ −0.016 0.169 −0.655 0.821 −0.032 0.025 0.067
PIB– −0.042 0.065 −0.348 0.336 −0.050 0.065 <0.001*
Frontal lobe PIB+ 0.065 0.193 −0.600 1.038 −0.014 0.117 <0.001*
PIB– −0.025 0.076 −0.346 0.538 −0.046 0.174 <0.001*
Parietal lobe PIB+ 0.011 0.186 −0.696 0.895 −0.017 0.042 0.004*
PIB– −0.022 0.081 −0.324 0.686 −0.044 0.190 <0.001*
Temporal lobe PIB+ −0.108 0.164 −0.787 0.648 −0.066 −0.063 <0.001*
PIB– −0.062 0.066 −0.386 0.226 −0.059 −0.028 0.007*
White matter PIB+ −0.152 0.170 −0.797 0.690 −0.054 −0.151 <0.001*
PIB– −0.029 0.066 −0.308 0.239 −0.039 0.083 <0.001*
Brainstem PIB+ −0.153 0.170 −0.797 0.690 −0.059 −0.151 <0.001*
PIB– −0.029 0.066 −0.308 0.239 −0.039 0.089 <0.001*
White matter + brainstem PIB+ −0.197 0.184 −0.879 0.628 −0.055 −0.223 <0.001*
PIB– −0.052 0.065 −0.371 0.138 −0.051 −0.014 0.179
Threshold 0.01 PIB+ −0.039 0.166 −0.655 0.820 −0.053 0.021 0.121
PIB– −0.023 0.066 −0.306 0.288 −0.037 0.132 <0.001*
Threshold 0.05 PIB+ −0.041 0.166 −0.656 0.816 −0.054 0.020 0.144
PIB– −0.020 0.067 −0.301 0.298 −0.035 0.140 <0.001*
Threshold 0.1 PIB+ −0.042 0.166 −0.657 0.812 −0.053 0.019 0.170
PIB– −0.015 0.070 −0.292 0.315 −0.032 0.156 <0.001*
SPM PIB+ −0.013 0.173 −0.645 0.856 −0.027 0.022 0.127
PIB– −0.038 0.067 −0.340 0.352 −0.050 0.107 <0.001*
*p < 0.05.
value closest to the expected value, as estimated before [34].
Therefore, the Threshold 0.1 method is the recommended
approach for the SRTM2 voxel-based analysis of dynamic PIB
PET images. While this study was done using a voxel-based
modeling approach (SRTM2), some of the results can be extended
to VOI-based modeling [such as regional time-activity curves
(TAC)]. However, the delineation of the threshold VOIs was
done using the BPSRTMND parametric maps, and these maps are
not available when performing TAC analysis. Thus, in the case
of VOI-basedmodeling, it might be optimal to select a predefined
VOI fromwhere to estimate k′2. In this scenario, theWhiteMatter
VOI seems to be the recommended region for estimating k′2,
for the same reasons that Threshold 0.1 was recommended for
voxel-based analysis.
In this study, all analyses focused on the use of a reference
tissue approach. Previous studies have shown that there is a
high correlation between BPSRTMND and BPND delivered by a
plasma-input two-tissue compartment model [10]. Since plasma
input data was not available for this study, no comparison with
the ground truth could be done, although there was a good
agreement between the median k′2 estimated from all subjects
and that seen in previous studies [10, 34]. Furthermore, another
limitation was the lack of a measure for quantifying the accuracy
of the parametric maps generated using both SRTM and SRTM2.
Moreover, this study was performed using PIB as a radiotracer,
but it can be assumed that the same results are applicable to
other tracers, such as [18F]Florbetapir, [18F]Florbetaben, and
[18F]Flutemetamol, since their target is also the deposit of Aβ
plaques in the brain [39]. However, further research is required
to confirm this.
In conclusion, this study aimed to assess the optimal method
for deriving and fixing k′2 to measure the binding potential
with SRTM2. It was found that the different approaches tested
yielded distinct k′2 estimates across methods and subject groups,
which, in turn, affected BPSRTM2ND estimates. In this study, it was
found that setting a threshold on BPSRTMND to select brain regions
or voxels to estimate k′2 is the best method for voxel-based
pharmacokinetic modeling of PIB PET scans.Moreover, for VOI-
based analysis of the images, a white matter volume of interest to
derive k′2 is a good alternative.
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